TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain

Antimicrob Agents Chemother. 2013 May;57(5):2410-2. doi: 10.1128/AAC.01761-12. Epub 2013 Mar 11.

Abstract

A Proteus mirabilis clinical strain (7001324) was isolated from urine sample of a patient hospitalized in a long-term-care facility. PCR and cloning experiments performed with this strain identified a novel TEM-type β-lactamase (TEM-187) differing by four amino acid substitutions (Leu21Phe, Arg164His, Ala184Val, and Thr265Met) from TEM-1. This characterization provides further evidence for the diversity of extended-spectrum β-lactamases (ESBL) produced by P. mirabilis and for their potential spread to other Enterobacteriaceae due to a lack of sensitive detection methods used in daily practice.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-Bacterial Agents / pharmacology*
  • Base Sequence
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Humans
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Proteus Infections / drug therapy
  • Proteus Infections / microbiology
  • Proteus mirabilis / drug effects*
  • Proteus mirabilis / enzymology
  • Proteus mirabilis / genetics
  • Proteus mirabilis / isolation & purification
  • beta-Lactamases / genetics*
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases

Associated data

  • GENBANK/HM246246